Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin: A Review in Type 1 Diabetes
Julia Paik, Hannah A. Blair
Drugs (2019) Vol. 79, Iss. 17, pp. 1877-1884
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Chemical synthesis of oligosaccharides and their application in new drug research
Zhimin Lv, Hongyu Liu, Huifang Hao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115164-115164
Open Access | Times Cited: 24
Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus
Le ZHOU, Xiaohong GENG, Qian Hu, et al.
Minerva Cardiology and Angiology (2024) Vol. 72, Iss. 3
Closed Access | Times Cited: 6
Expectations in children with glomerular diseases from SGLT2 inhibitors
Luigi Cirillo, Fiammetta Ravaglia, Carmela Errichiello, et al.
Pediatric Nephrology (2022) Vol. 37, Iss. 12, pp. 2997-3008
Closed Access | Times Cited: 27
Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage
Jianhua Zeng, Hao Huang, Yan Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
Simultaneous estimation of dapagliflozin and linagliptin using reverse phase-HPLC with photo diode array (PDA)
Usmangani K. Chhalotiya, Anchal Shukla, Dimal A. Shah, et al.
Journal of Chemical Metrology (2024), Iss. 1, pp. 19-29
Open Access | Times Cited: 5
Metabolomics-driven elucidation of the synergistic therapeutic mechanism of a novel SGLT-2/PPAR-γ dual receptor supramolecular system for treatment diabetes and obesity
Saisai Ren, Han Hao, Wei Guo, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101308-101308
Open Access
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update
Martha Nicholson, Randa Ghazal Asswad, John Wilding
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 17, pp. 2303-2310
Open Access | Times Cited: 24
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Jennifer Matthews, Lakshini Y. Herat, Markus P. Schlaich, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14243-14243
Open Access | Times Cited: 10
A Drug Safety Evaluation of Dapagliflozin for Diabetic Nephropathies in Patients with Cardiovascular Risk
Aayushi Sood, Aanchal Sawhney, Benjamin Borokhovsky, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
Anne L. Peters, Darren K. McGuire, Thomas Danne, et al.
Diabetes Care (2020) Vol. 43, Iss. 11, pp. 2713-2720
Open Access | Times Cited: 22
The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
Gabriella di Mauro, Annamaria Mascolo, Mario Gaio, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 286-286
Open Access | Times Cited: 14
Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review)
Octavian Vasiliu
Experimental and Therapeutic Medicine (2023) Vol. 25, Iss. 3
Open Access | Times Cited: 7
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
Hannah A. Blair
American Journal of Cardiovascular Drugs (2021) Vol. 21, Iss. 6, pp. 701-710
Open Access | Times Cited: 17
The OTUD1-Notch2-ICD axis orchestrates allogeneic T cell–mediated graft-versus-host disease
Qiao Cheng, Dong Wang, Xiaoxuan Lai, et al.
Blood (2022) Vol. 141, Iss. 12, pp. 1474-1488
Closed Access | Times Cited: 11
The Use of Vildagliptin-Dapagliflozin Fixed Dose Combination in Different Patient Profiles in Indian Settings: An Opinion-Based Consensus
U. Garg, Ritesh Kumar Agrawala, SS Akbar, et al.
International Journal of Current Science Research and Review (2023) Vol. 06, Iss. 03
Open Access | Times Cited: 5
On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
Takeshi Horii, Yoichi Oikawa, Koichiro Atsuda, et al.
Journal of Diabetes Investigation (2021) Vol. 12, Iss. 9, pp. 1586-1593
Open Access | Times Cited: 12
A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus
Ahmed Abu‐Zaid, Abdulaziz Khalaf Altowairqi, Thusharika Dissanayaka, et al.
Pharmacological Research (2021) Vol. 165, pp. 105456-105456
Closed Access | Times Cited: 11
Overlapping risk factors for diabetic ketoacidosis in patients with type 1 diabetes on ipragliflozin: case analysis of spontaneous reports in Japan from a pharmacovigilance safety database
Norio Abiru, Yoshino Nakatsuji, Masahiro Noguchi, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 8, pp. 697-706
Open Access | Times Cited: 4
Reduced expression of OXPHOS and DNA damage genes is linked to protection from microvascular complications in long-term type 1 diabetes: the PROLONG study
Türküler Özgümüş, Oksana Sulaieva, Leon Eyrich Jessen, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 8
Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus
Eva Kráľová, Margaréta Marušáková, Katarína Hadová, et al.
Journal of Pharmacy and Pharmacology (2021) Vol. 73, Iss. 6, pp. 778-784
Closed Access | Times Cited: 7
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus
Ning Li, Ruimin Chen, Kewei Liu
Clinical Drug Investigation (2020) Vol. 40, Iss. 11, pp. 991-1000
Closed Access | Times Cited: 6
Insulin, but Not Metformin, Supports Wound Healing Process in Rats with Streptozotocin-Induced Diabetes
Mateusz Mieczkowski, Beata Mrozikiewicz‐Rakowska, Tomasz J. Siwko, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 1505-1517
Open Access | Times Cited: 6
Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients
Dongdong Wang, Su‐Mei He, Yan Han, et al.
Journal of Clinical Pharmacy and Therapeutics (2021) Vol. 47, Iss. 2, pp. 237-242
Open Access | Times Cited: 5
Hundert Jahre – Insulin bleibt aktuell und notwendig
Rüdiger Landgraf, Jens Aberle
Diabetologie und Stoffwechsel (2021) Vol. 16, Iss. 02, pp. 149-161
Open Access | Times Cited: 4
Light-Mediated Cross-Coupling of Anomeric Trifluoroborates
Eric Miller, Maciej A. Walczak
(2021)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top